NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

Core Viewpoint - Nanobiotix has been admitted to the CAC Mid 60 and SBF 120 indices, enhancing its visibility among institutional investors and strengthening its presence in European equity markets [1][2][3]. Group 1: Company Overview - Nanobiotix is a late-stage clinical biotechnology company focused on physics-based therapeutic approaches for cancer and other major diseases [1][4]. - The company is headquartered in Paris, France, and has been listed on Euronext Paris since 2012 and on Nasdaq since December 2020 [5]. - Nanobiotix holds over 25 umbrella patents related to three nanotechnology platforms, which include applications in oncology, bioavailability, and disorders of the central nervous system [6]. Group 2: Market Impact - Inclusion in the CAC Mid 60 and SBF 120 indices is expected to broaden Nanobiotix's visibility and increase exposure to index-linked investment strategies [2]. - The admission reflects the financial markets' confidence in Nanobiotix's long-term strategy and the potential of its nanotherapeutic solutions [3].